WO1987000613A1
(en)
*
|
1985-07-19 |
1987-01-29 |
Armtech Limited |
A disc magazine firearm
|
US7863444B2
(en)
*
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
US7223724B1
(en)
*
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
US6921763B2
(en)
*
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
US7273751B2
(en)
*
|
2000-08-04 |
2007-09-25 |
Human Genome Science, Inc. |
Vascular endothelial growth factor-2
|
MXPA03008560A
(es)
*
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US7208582B2
(en)
*
|
2001-04-13 |
2007-04-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US20050232921A1
(en)
*
|
2001-04-13 |
2005-10-20 |
Rosen Craig A |
Vascular endothelial growth factor 2
|
CA2444624A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
ATE386727T1
(de)
|
2001-04-30 |
2008-03-15 |
Glaxo Group Ltd |
Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
|
DE60228103D1
(de)
*
|
2001-10-02 |
2008-09-18 |
Smithkline Beecham Corp |
Chemische verbindungen
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
US6695881B2
(en)
|
2002-04-29 |
2004-02-24 |
Alcon, Inc. |
Accommodative intraocular lens
|
US20040033986A1
(en)
*
|
2002-05-17 |
2004-02-19 |
Protopopova Marina Nikolaevna |
Anti tubercular drug: compositions and methods
|
US7456222B2
(en)
*
|
2002-05-17 |
2008-11-25 |
Sequella, Inc. |
Anti tubercular drug: compositions and methods
|
US7652039B2
(en)
*
|
2002-05-17 |
2010-01-26 |
Sequella, Inc. |
Methods of use and compositions for the diagnosis and treatment of infectious disease
|
AU2003254051A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
WO2004009602A1
(en)
*
|
2002-07-23 |
2004-01-29 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
US20060167020A1
(en)
*
|
2002-07-23 |
2006-07-27 |
Dickerson Scott H |
Pyrazolopyrimidines as kinase inhibitors
|
WO2004013141A1
(en)
|
2002-08-06 |
2004-02-12 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
GB0226370D0
(en)
*
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
GB0230089D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
WO2004100868A2
(en)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
TWI335328B
(en)
*
|
2003-07-14 |
2011-01-01 |
Arena Pharm Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
|
WO2005034857A2
(en)
*
|
2003-09-05 |
2005-04-21 |
Sequella, Inc. |
Methods and compositions comprising diamines as new anti-tubercular therapeutics
|
CN1878568A
(zh)
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
EP1730148A4
(en)
*
|
2004-02-03 |
2009-08-19 |
Abbott Lab |
USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
|
KR100843526B1
(ko)
*
|
2004-02-27 |
2008-07-03 |
에프. 호프만-라 로슈 아게 |
피라졸의 접합 유도체
|
BRPI0508970A
(pt)
*
|
2004-03-19 |
2007-08-21 |
Penn State Res Found |
método combinatórios e composições para o tratamento de melanoma
|
WO2005112936A1
(en)
*
|
2004-05-14 |
2005-12-01 |
The Regents Of The University Of Michigan |
Compositions and methods relating to protein kinase inhibitors
|
WO2005117932A1
(en)
*
|
2004-06-04 |
2005-12-15 |
The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations |
Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
JP2008519030A
(ja)
|
2004-11-05 |
2008-06-05 |
パリンゲン インコーポレーテッド |
抗体で誘導される細胞膜損傷
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
DOP2006000009A
(es)
*
|
2005-01-13 |
2006-08-15 |
Arena Pharm Inc |
Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
|
JP5147401B2
(ja)
*
|
2005-09-06 |
2013-02-20 |
塩野義製薬株式会社 |
Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
|
US20070072933A1
(en)
*
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an ocular agent
|
EA015463B1
(ru)
|
2005-11-17 |
2011-08-30 |
Оси Фармасьютикалз, Инк. |
КОНДЕНСИРОВАННОЕ БИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ - ИНГИБИТОР mTOR, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ РАКА
|
PE20070855A1
(es)
*
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
JP5249776B2
(ja)
*
|
2005-12-02 |
2013-07-31 |
バイエル・ヘルスケア・エルエルシー |
過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された4−アミノ−ピロロトリアジン誘導体
|
US8338594B2
(en)
*
|
2005-12-02 |
2012-12-25 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
TW200801008A
(en)
*
|
2005-12-29 |
2008-01-01 |
Abbott Lab |
Protein kinase inhibitors
|
EP1981888A4
(en)
*
|
2006-01-13 |
2010-10-13 |
Pharmacyclics Inc |
TYROSINE KINASE INHIBITORS AND USES THEREOF
|
ATE525072T1
(de)
*
|
2006-02-09 |
2011-10-15 |
Athersys Inc |
Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen
|
US7723330B2
(en)
|
2006-03-07 |
2010-05-25 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
AU2007347115A1
(en)
|
2006-04-04 |
2008-10-23 |
The Regents Of The University Of California |
PI3 kinase antagonists
|
NL2000613C2
(nl)
*
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
GB0610242D0
(en)
*
|
2006-05-23 |
2006-07-05 |
Novartis Ag |
Organic compounds
|
SI2530083T1
(sl)
|
2006-09-22 |
2016-09-30 |
Pharmacyclics Llc |
Inhibitorji Bruton tirozin kinaze
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
EP2134677B1
(en)
|
2006-12-20 |
2011-10-12 |
Bayer HealthCare LLC |
4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
RU2446796C2
(ru)
*
|
2006-12-26 |
2012-04-10 |
Фармасайкликс, Инк. |
Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
|
US20080200458A1
(en)
*
|
2007-01-18 |
2008-08-21 |
Joseph Barbosa |
Methods and compositions for the treatment of body composition disorders
|
US20080194557A1
(en)
*
|
2007-01-18 |
2008-08-14 |
Joseph Barbosa |
Methods and compositions for the treatment of pain, inflammation and cancer
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
AU2008232762B2
(en)
|
2007-03-28 |
2013-09-19 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
MX2010000617A
(es)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
|
EP2178869B1
(en)
*
|
2007-08-17 |
2013-06-12 |
LG Life Sciences Ltd. |
Indole compounds as an inhibitor of cellular necrosis
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
EP2240452B1
(en)
|
2008-01-04 |
2019-05-29 |
Intellikine, LLC |
1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as pi3 kinase modulators, their compositions and uses
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US20110020326A1
(en)
*
|
2008-03-04 |
2011-01-27 |
Children's Medical Center Corporation |
Method of treating polycystic kidney disease
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
US20090281054A1
(en)
*
|
2008-05-06 |
2009-11-12 |
Venkata Reddy |
Compositions and methods comprising capuramycin analogues
|
US20100101977A1
(en)
*
|
2008-06-05 |
2010-04-29 |
United Comb & Novelty Corporation |
Stackable Packaging For Lipped Containers
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8946239B2
(en)
|
2008-07-10 |
2015-02-03 |
Duquesne University Of The Holy Spirit |
Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
|
CN102159214A
(zh)
*
|
2008-07-16 |
2011-08-17 |
药品循环公司 |
用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
AU2009305669A1
(en)
*
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
CA2742306A1
(en)
*
|
2008-11-03 |
2010-05-06 |
Chemocentryx, Inc. |
Compounds for the treatment of osteoporosis and cancers
|
JP2012524058A
(ja)
*
|
2009-04-15 |
2012-10-11 |
フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ |
血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
CA2771895A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Array Biopharma Inc. |
Raf inhibitor compounds and methods of use thereof
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
CN103221391B
(zh)
|
2010-01-27 |
2018-07-06 |
艾尼纳制药公司 |
(R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
|
KR101661383B1
(ko)
*
|
2010-02-08 |
2016-09-29 |
머크 샤프 앤 도메 비.브이. |
8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물
|
AU2011255218B2
(en)
|
2010-05-21 |
2015-03-12 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
CA2800521A1
(en)
|
2010-05-24 |
2011-12-01 |
Toa Eiyo Ltd. |
Fused imidazole derivative
|
US20120087915A1
(en)
|
2010-06-03 |
2012-04-12 |
Pharmacyclics, Inc. |
Use of inhibitors of bruton's tyrosine kinase (btk)
|
PE20131371A1
(es)
|
2010-09-22 |
2013-11-25 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
CN106619647A
(zh)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
WO2012158764A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
CA2840687C
(en)
|
2011-07-01 |
2020-04-28 |
Dana-Farber Cancer Institute, Inc. |
Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
|
MX2014000518A
(es)
|
2011-07-13 |
2014-05-30 |
Pharmacyclics Inc |
Inhibidores de la tirosina quinasa de bruton.
|
EP2548877A1
(en)
*
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
WO2013077921A2
(en)
*
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
UA110853C2
(uk)
|
2011-09-13 |
2016-02-25 |
Фармасайклікс, Інк. |
Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
IN2014MN01781A
(zh)
|
2012-02-08 |
2015-07-03 |
Igm Biosciences Inc |
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
KR101972990B1
(ko)
*
|
2012-05-31 |
2019-04-26 |
파마사이언스 인크. |
단백질 키나제 저해제
|
US9296753B2
(en)
|
2012-06-04 |
2016-03-29 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
GB201211309D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Fujifilm Mfg Europe Bv |
Process for preparing membranes
|
EP3550031A1
(en)
|
2012-07-24 |
2019-10-09 |
Pharmacyclics, LLC |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
WO2014017659A1
(ja)
|
2012-07-27 |
2014-01-30 |
独立行政法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
EP3181567B1
(en)
|
2012-09-10 |
2019-03-20 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
MA38183A1
(fr)
|
2012-11-15 |
2017-03-31 |
Pharmacyclics Inc |
Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
|
PT2928898T
(pt)
|
2012-12-07 |
2021-07-05 |
Venatorx Pharmaceuticals Inc |
Inibidores de beta-lactamase
|
EP2943204B1
(en)
|
2013-01-10 |
2019-03-13 |
Venatorx Pharmaceuticals Inc |
Beta-lactamase inhibitors
|
US9593106B2
(en)
|
2013-02-07 |
2017-03-14 |
Heptares Therapeutics Limited |
Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
|
SI2970291T1
(sl)
*
|
2013-03-15 |
2022-07-29 |
Janssen Pharmaceutica, N.V. |
Postopki in vmesne spojine za pripravo zdravila
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
HUE031980T2
(en)
|
2013-04-25 |
2017-08-28 |
Beigene Ltd |
Condensed heterocyclic compounds as protein kinase inhibitors
|
CA2919996A1
(en)
|
2013-08-02 |
2015-02-05 |
Pharmacyclics Llc |
Methods for the treatment of solid tumors
|
CA2920534A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics Llc |
Methods for the treatment of her2 amplified cancer
|
WO2015035606A1
(en)
|
2013-09-13 |
2015-03-19 |
Beigene, Ltd. |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
WO2015048689A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
SG10201902074UA
(en)
|
2013-10-04 |
2019-04-29 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
KR102452866B1
(ko)
|
2013-10-25 |
2022-10-07 |
파마싸이클릭스 엘엘씨 |
이식편 대 숙주 질환의 치료 및 예방 방법
|
CA2932351A1
(en)
|
2013-12-13 |
2015-06-18 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
SG11201605417QA
(en)
*
|
2014-02-03 |
2016-08-30 |
Cadila Healthcare Ltd |
Heterocyclic compounds
|
CN114404427A
(zh)
*
|
2014-02-13 |
2022-04-29 |
配体药物公司 |
前药化合物及其用途
|
KR20220027271A
(ko)
|
2014-02-21 |
2022-03-07 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제의 염 및 고체 형태
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
CA2942528A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
EP3160505A4
(en)
|
2014-07-03 |
2018-01-24 |
BeiGene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
AU2015300798A1
(en)
|
2014-08-07 |
2017-02-02 |
Pharmacyclics Llc |
Novel formulations of a Bruton's tyrosine kinase inhibitor
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ITRM20140620A1
(it)
|
2014-10-30 |
2016-04-30 |
Lead Discovery Siena S R L |
Compounds and uses thereof
|
BR112017008809A2
(pt)
|
2014-11-05 |
2017-12-19 |
Flexus Biosciences Inc |
agentes imunorreguladores
|
UY36390A
(es)
*
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
CN104478884A
(zh)
*
|
2014-12-05 |
2015-04-01 |
广东东阳光药业有限公司 |
一种中间体的制备方法
|
CN107257686B
(zh)
|
2014-12-18 |
2021-01-29 |
普林斯匹亚生物制药公司 |
天疱疮的治疗
|
US10167451B2
(en)
|
2014-12-22 |
2019-01-01 |
The Chinese University Of Hong Kong |
Combinational use of mechanical manipulation and programin derivatives to increase Oct4, Sox2, or Nanog expression in fibroblasts
|
JP6736253B2
(ja)
*
|
2014-12-22 |
2020-08-05 |
ザ チャイニーズ ユニバーシティ オブ ホンコン |
体細胞から多能性幹細胞を作製するための機械的操作とプログラミンの併用
|
EP3236959A4
(en)
|
2014-12-23 |
2018-04-25 |
Dana Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
CN105777755A
(zh)
*
|
2015-01-07 |
2016-07-20 |
常州百敖威生物科技有限公司 |
一种伊鲁替尼中间体3-碘-1h-吡唑并[3,4-d]嘧啶-4-胺的制备方法
|
SG11201707122QA
(en)
|
2015-03-03 |
2017-09-28 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
IL285890B
(en)
|
2015-06-22 |
2022-07-01 |
Arena Pharm Inc |
Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
|
EP3313839A1
(en)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
JP7028766B2
(ja)
|
2015-09-09 |
2022-03-02 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
US10160761B2
(en)
|
2015-09-14 |
2018-12-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
US10611766B2
(en)
*
|
2015-09-16 |
2020-04-07 |
Loxo Oncology Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
DK3390395T3
(da)
|
2015-12-16 |
2020-09-28 |
Loxo Oncology Inc |
Forbindelser, der kan anvendes som kinase-inhibitorer
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
KR102515813B1
(ko)
|
2016-06-29 |
2023-03-30 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
NZ751418A
(en)
*
|
2016-08-16 |
2023-04-28 |
Beigene Ltd |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
CA3034326A1
(en)
|
2016-08-19 |
2018-02-22 |
Beigene, Ltd. |
Use of a combination comprising a btk inhibitor for treating cancers
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
US11534424B2
(en)
|
2017-02-16 |
2022-12-27 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
KR20200020902A
(ko)
|
2017-06-26 |
2020-02-26 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
EP3737676B1
(en)
|
2018-01-09 |
2024-03-06 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
CN108299311A
(zh)
*
|
2018-02-28 |
2018-07-20 |
杭州福斯特药业有限公司 |
一种5-溴-2-氯-n-环戊基嘧啶-4-胺的制备方法
|
CN111171035B
(zh)
*
|
2018-11-13 |
2021-03-30 |
山东大学 |
4-苯氧基苯基吡唑并嘧啶酰胺衍生物的制备方法和应用
|
CN111454268B
(zh)
*
|
2019-01-18 |
2023-09-08 |
明慧医药(上海)有限公司 |
作为布鲁顿酪氨酸激酶抑制剂的环状分子
|
AU2020301399A1
(en)
*
|
2019-06-24 |
2021-12-02 |
Dana-Farber Cancer Institute, Inc. |
HCK degraders and uses thereof
|
CN110511225B
(zh)
*
|
2019-08-19 |
2023-07-18 |
杭州中美华东制药有限公司 |
一种伊布替尼中间体的合成方法
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
US11787796B2
(en)
|
2019-09-18 |
2023-10-17 |
Takeda Pharmaceutical Company Limited |
Plasma Kallikrein inhibitors and uses thereof
|
CA3157331A1
(en)
*
|
2019-10-08 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
|
CN112961158B
(zh)
*
|
2020-03-05 |
2022-07-01 |
四川大学华西医院 |
氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途
|
WO2021184154A1
(en)
*
|
2020-03-16 |
2021-09-23 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
TWI797711B
(zh)
|
2020-08-13 |
2023-04-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr及其突變抑制劑,其製備方法和應用
|
WO2022109001A1
(en)
|
2020-11-18 |
2022-05-27 |
Deciphera Pharmaceuticals, Llc |
Gcn2 and perk kinase inhibitors and methods of use thereof
|
EP4308229A1
(en)
*
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Inhibitors of plasma kallikrein
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
CN115650986B
(zh)
*
|
2022-10-22 |
2024-07-30 |
浙江工业大学 |
肉桂酰氨基吡唑并[3,4-d]嘧啶类化合物及其制备和应用
|